Article Text

Download PDFPDF
CASE REPORT
Recombinant tissue plasminogen activator for massive pulmonary thromboembolism
  1. Kouki Samejima1,
  2. Yasushi Takai2,
  3. Hideyoshi Matsumura1,
  4. Hiroyuki Seki1
  1. 1Division of Maternal and Fetal Medicine, Center for Maternal, Fetal and Neonatal Medicine, Saitama Medical Center, Saitama Medical University, Saitama, Japan
  2. 2Department of Obstetrics and Gynecology, Center for Maternal, Fetal and Neonatal Medicine, Saitama Medical Center, Saitama Medical University, Saitama, Japan
  1. Correspondence to Dr Yasushi Takai, yastakai{at}saitama-med.ac.jp

Summary

Pulmonary thromboembolism (PTE) can result in significant adverse maternal and fetal outcomes. Monteplase—a recombinant tissue plasminogen activator—is considered effective for the treatment of PTE; however, only a few reports have described cases wherein surgical procedures were performed following treatment with monteplase. Here, we present a patient diagnosed with a massive PTE at 28 weeks of gestation leading to maternal cardiac arrest and intrauterine fetal death. The patient was treated with percutaneous cardiopulmonary support and monteplase. Thrombolysis was achieved 30 min after its administration. The patient went into spontaneous labour and delivered a stillborn vaginally. Using gauze tamponade and uterotonic agents, haemostasis was achieved after 4 h, and bleeding completely ceased after 7 h. Thus, we suggest that a thrombolytic agent can be administered in critical cases, even if delivery is expected shortly.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.